{"denoms":[{"counts":[{"groupId":"BG000","value":"5377"}],"units":"Participants"}],"groups":[{"description":"All patients receive cytarabine intrathecally (IT) on day 1; vincristine IV on days 1, 8, 15, and 22; dexamethasone IV or orally (PO) twice daily (BID) on days 1-28; pegaspargase intramuscularly (IM) (may give IV over 1 to 2 hours) on day 4, 5, or 6; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease). Patients with Down syndrome (DS) receive leucovorin calcium PO at 48 and 60 hours after each dose of methotrexate IT. Patients are assessed for response on day 29. Patients with M1 bone marrow AND minimal residual disease (MRD) \\< 0.1% OR MRD \\>= 0.1% and \\< 1% proceed to therapy in part II. Patients with M2 bone marrow OR M1 bone marrow AND MRD \\>= 1% proceed to extended induction therapy. Patients with M3 bone marrow are removed from the study.\n\ncytarabine: Given IV or SC\n\ndexamethasone: Given IV or PO\n\npegaspargase: Given IM\n\nmethotrexate: Given IM or IT\n\nvincristine sulfate: Given IV","id":"BG000","title":"Group 0 Induction Therapy"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5377"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"2.10","value":"4.45"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2489"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2888"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1097"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"4038"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"242"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"253"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"24"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"326"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"4046"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"692"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5377"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}